Welcome to our dedicated page for Propanc Biopharma SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Propanc Biopharma, Inc. filings document a development-stage biopharmaceutical issuer centered on PRP, a proenzyme formulation using trypsinogen and chymotrypsinogen for recurrent and metastatic cancer programs. Registration statements and amendments disclose the company’s business, financial statements, clinical-development plans, risk factors, offering terms, and capital needs.
Material-event reports cover financing and governance actions, including Series C Preferred Stock, related warrants, amendments to charter documents, board changes, and Nasdaq listing-compliance notices. The filing record also details capitalization, preferred-stock rights and conversion mechanics, unregistered equity sales, and public-company reporting obligations tied to Propanc’s oncology development strategy.
Propanc Biopharma (PPCB) filed its quarterly report for the three months ended September 30, 2025. The company reported no revenue and a net loss of $4,837,738, compared with a $354,310 loss a year ago. Operating expenses rose to $4,673,564 (from $290,790), driven mainly by administration expenses of $4,598,574, which included non‑cash items such as amortization of prepaid stock-based expenses.
Cash increased to $602,737 from $12,088, helped by financing inflows. The company completed an equity raise on August 18, 2025, selling 1,000,000 shares for $4,000,000 in gross proceeds and receiving approximately $3.3 million net. Total assets were $17,975,681, led by significant prepaid expenses, while total liabilities declined to $3,614,514 as convertible notes and related derivative balances decreased. The filing notes substantial doubt about the company’s ability to continue as a going concern. Common shares outstanding were 12,806,748 at September 30, 2025, and 13,364,244 as of November 13, 2025.
Propanc Biopharma (PPCB) closed a private placement with Hexstone Capital, receiving $1,000,099 in cash for 100 shares of Series C Preferred Stock and issuing a warrant to purchase up to 9,900 additional Series C Preferred shares at an exercise price of $10,000 per warrant share. The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D.
The company also created and authorized up to 9,900 shares of Series C Preferred through a Certificate of Designation. Each preferred share has a stated amount of $10,000 and is convertible into common stock at the lesser of a fixed $5.00 per share or 85% of the lowest trading price during a defined period with a five trading day minimum and a volume condition. This brings in immediate cash and sets terms for potential future conversions and warrant exercises.
Propanc Biopharma (PPCB) entered a Securities Purchase Agreement for a private placement of a new Series C Preferred Stock class. The deal with Hexstone Capital provides for the issuance of 100 Series C Preferred shares at closing and a Warrant to purchase up to an additional 9,900 Series C Preferred shares. Each Series C Preferred share is convertible into common stock at the lesser of a fixed $5.00 per-share conversion price or 85% of the lowest trading price during a defined period tied to a holder’s conversion notice, with a five trading day minimum. The closing is conditioned on filing the Certificate of Designation for the Series C Preferred with Delaware.
Propanc Biopharma, Inc. (PPCB) reported financials highlighting severe liquidity and solvency pressures. The company recorded an accumulated deficit of $125,621,520 and net cash used in operations of $405,168. It had no cash equivalents at June 30, 2025. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
The filing discloses a 1:60,000 Reverse Stock Split effective January 29, 2025, numerous loans and convertible notes with defaults or past due maturities, and debt-exchange transactions that settled loans for common stock (e.g., 30,000 shares issued to settle $86,248 of loans). The company lists extensive granted patents and patent validations for its proenzyme/proenzyme compositions across many jurisdictions. It completed a registered offering that produced $3.34 million net proceeds.